Identification
Instrument name
PREDILIFE
Symbol
ALPRE
ISIN code
FR0010169920
Exchange / Market
Euronext Growth
Trading location
Paris
Products family
Stocks
ICB
Software
Operation
IPO date
IPO price
EUR 9.30
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 8.76- EUR 11.84

Company profile

Predilife (formerly Statlife) specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of 1,000,000 American women and 300,000 French women.

Source: Cofisem - Last Update: 06 May 2020
Key Executives
Chairman and Chief Executive Officer Stéphane Ragusa
Deputy CEO Pierre Verdet
Director Research & Development Emilien Gauthier
Source: Cofisem - Last Update: 25 Mar 2019
Key figures
Millenium 2019 2018 2017 2016
Net sales 23 17 37
Consumed purchases 8 2 2
Payroll 1,064 1,079 976 844
Operating profit -2,423 -2,355 -1,875 -1,596
Income tax 372 250 -175 -151
Net income -2,102 -2,371 -1,655 -1,485
Net consolidated income (Group share) -2,102 -2,371 -1,655 -1,485
Fiscal year end 12.19 12.18 12.17 12.16
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 06 May 2020
Shareholder information
 %
Source: Cofisem - Last Update: 06 May 2020